These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 29173297)
1. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease. Ebato T; Ogata S; Ogihara Y; Fujimoto M; Kitagawa A; Takanashi M; Ishii M J Pediatr; 2017 Dec; 191():140-144. PubMed ID: 29173297 [TBL] [Abstract][Full Text] [Related]
2. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370 [TBL] [Abstract][Full Text] [Related]
3. Methylprednisolone pulse and prednisolone for intensification of primary treatment in Kawasaki disease patients at high risk of treatment resistance: a multicenter prospective cohort study. Miura M; Miyata K; Kaneko T; Akahoshi S; Morikawa Y; Matsushima T; Sakakibara H; Kobayashi T; Nakamura T; Takahashi T; Nakazawa M; Shibata A; Yamagishi H Eur J Pediatr; 2024 Oct; 183(10):4265-4274. PubMed ID: 39048743 [TBL] [Abstract][Full Text] [Related]
4. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease. Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091 [TBL] [Abstract][Full Text] [Related]
5. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population. Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390 [TBL] [Abstract][Full Text] [Related]
6. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review. Crayne CB; Mitchell C; Beukelman T Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M; Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183 [TBL] [Abstract][Full Text] [Related]
8. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms. Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995 [TBL] [Abstract][Full Text] [Related]
9. Extremely refractory Kawasaki disease with disseminated intravascular coagulation. Koh YK; Lee JH; Park YB Cardiol Young; 2017 Jul; 27(5):1004-1007. PubMed ID: 28264746 [TBL] [Abstract][Full Text] [Related]
10. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India. Pilania RK; Jindal AK; Johnson N; Prithvi A; Vignesh P; Suri D; Rawat A; Gupta A; Singh S Rheumatology (Oxford); 2021 Jul; 60(7):3413-3419. PubMed ID: 33221920 [TBL] [Abstract][Full Text] [Related]
11. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997 [TBL] [Abstract][Full Text] [Related]
12. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin. Matsuoka R; Furuno K; Nanishi E; Onoyama S; Nagata H; Yamamura K; Sugitani Y; Kuraoka A; Mizuno Y; Sagawa K; Honjo S; Hara T; Ohga S J Pediatr; 2020 Dec; 227():224-230.e3. PubMed ID: 32810506 [TBL] [Abstract][Full Text] [Related]
13. [Retrospective analysis of infliximab in the treatment of Kawasaki disease]. Xie LP; Zhao L; Chu C; He L; Liang XC; Sun SN; Zhao QM; Wang F; Cao YY; Lin YX; Zeng ZQ; Wu L; Huang GY; Liu F Zhonghua Er Ke Za Zhi; 2022 Jan; 60(1):14-19. PubMed ID: 34986617 [No Abstract] [Full Text] [Related]
14. Infliximab plus plasma exchange rescue therapy in Kawasaki disease. Sonoda K; Mori M; Hokosaki T; Yokota S J Pediatr; 2014 May; 164(5):1128-1132.e1. PubMed ID: 24560183 [TBL] [Abstract][Full Text] [Related]
15. Response of refractory Kawasaki disease to intravenous methylprednisolone. Shah I; Prabhu SS Ann Trop Paediatr; 2009 Mar; 29(1):51-3. PubMed ID: 19222935 [TBL] [Abstract][Full Text] [Related]
16. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab. O'connor MJ; Saulsbury FT Clin Pediatr (Phila); 2007 May; 46(4):345-8. PubMed ID: 17475994 [TBL] [Abstract][Full Text] [Related]
17. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange. Fujimaru T; Ito S; Masuda H; Oana S; Kamei K; Ishiguro A; Kato H; Abe J Cytokine; 2014 Dec; 70(2):156-60. PubMed ID: 25082649 [TBL] [Abstract][Full Text] [Related]
18. Infliximab as a novel therapy for refractory Kawasaki disease. Weiss JE; Eberhard BA; Chowdhury D; Gottlieb BS J Rheumatol; 2004 Apr; 31(4):808-10. PubMed ID: 15088313 [TBL] [Abstract][Full Text] [Related]
19. [Kawasaki disease in children--9 years experience]. Kowalczyk M; Kawalec W; Daszkowska-York J; Turska-Kmieć A; Brzezińska-Rajszys G; Sobielarska D; Ziółkowska L; Kościesza A; Jagiełłowicz D; Mirecka-Rola A Med Wieku Rozwoj; 2005; 9(2):179-93. PubMed ID: 16085959 [TBL] [Abstract][Full Text] [Related]
20. [Kawasaki disease: what you need to know]. Bajolle F; Laux D Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]